Literature DB >> 19497068

Effect of a triple blockade of the renin-angiotensin-system in recurrent focal segmental glomerulosclerosis after kidney transplantation.

Verena Freiberger1, Kerstin Amann, Uwe Heemann, Helga Frank.   

Abstract

Recurrent focal segmental glomerulosclerosis (FSGS) after renal transplantation with nephrotic syndrome is a serious problem with a high risk of graft loss. The therapeutic role of renin-angiotensin-system (RAS) blockers in recurrent FSGS is not clear. We present the safety and efficacy of an intensified triple RAS blockade with an ACE-inhibitor, an AT 1 receptor blocker and the direct renin inhibitor aliskiren in a 29-year-old renal transplant recipient with biopsy proven recurrence of FSGS and relapsing severe nephrotic syndrome. We subsequently used full dose ramipril, candesartan and aliskiren under a close monitoring of kidney function and electrolytes and examined the effect on proteinuria, clinical course and tolerability over 12 months. We found a significant and sustained antiproteinuric effect under triple RAS blockade. RAS blockade was generally well tolerated. This can offer a new therapeutic approach in selected hypertensive patients with recurrent FSGS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19497068     DOI: 10.1111/j.1432-2277.2009.00897.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  9 in total

1.  Optimal renin-angiotensin system blockade-wishful thinking?

Authors:  Harikrishna Makani; Sripal Bangalore; Franz H Messerli
Journal:  Nat Rev Cardiol       Date:  2013-07-02       Impact factor: 32.419

2.  Rituximab in post-transplant pediatric recurrent focal segmental glomerulosclerosis.

Authors:  Juhi Kumar; Ibrahim F Shatat; Amy L Skversky; Robert P Woroniecki; Marcela Del Rio; Eduardo M Perelstein; Valerie L Johnson; Shefali Mahesh
Journal:  Pediatr Nephrol       Date:  2012-10-04       Impact factor: 3.714

Review 3.  Direct inhibition of plasmatic renin activity with aliskiren: a promising but under-investigated therapeutic option for non-diabetic glomerulonephritis.

Authors:  Mariadelina Simeoni; Ramona Nicotera; Maria Colao; Maria Lucia Citraro; Elena Pelagi; Annamaria Cerantonio; Nicola Comi; Giuseppe Coppolino; Giorgio Fuiano
Journal:  Int Urol Nephrol       Date:  2015-10-05       Impact factor: 2.370

Review 4.  Update on the treatment of focal segmental glomerulosclerosis in renal transplantation.

Authors:  Maria Messina; Ester Gallo; Alberto Mella; Fabiola Pagani; Luigi Biancone
Journal:  World J Transplant       Date:  2016-03-24

Review 5.  Recent progress in the pathophysiology and treatment of FSGS recurrence.

Authors:  P Cravedi; J B Kopp; G Remuzzi
Journal:  Am J Transplant       Date:  2013-01-11       Impact factor: 8.086

6.  The factors that may predict response to rituximab therapy in recurrent focal segmental glomerulosclerosis: a systematic review.

Authors:  Carlos E Araya; Vikas R Dharnidharka
Journal:  J Transplant       Date:  2011-11-24

Review 7.  Optimal management of primary focal segmental glomerulosclerosis in adults.

Authors:  Séverine Beaudreuil; Hans Kristian Lorenzo; Michele Elias; Erika Nnang Obada; Bernard Charpentier; Antoine Durrbach
Journal:  Int J Nephrol Renovasc Dis       Date:  2017-05-10

Review 8.  FSGS Recurrence in Adults after Renal Transplantation.

Authors:  Michael Rudnicki
Journal:  Biomed Res Int       Date:  2016-04-10       Impact factor: 3.411

9.  Treatment of Focal Segmental Glomerulosclerosis Recurrence in the Renal Allograft: A Report of Two Cases.

Authors:  Minh-Ha Tran; Cynthia Chan; Whitney Pasch; Philip Carpenter; Hirohito Ichii; Clarence Foster
Journal:  Case Rep Nephrol Dial       Date:  2016-03-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.